GDTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
CytoMed Therapeutics Ltd
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026
$0.85−0.03 (-3.17%)
Close on Oct 19, 2026
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
CytoMed Therapeutics has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements CytoMed Therapeutics filed with the SEC
THERAPEUTICS LIMITED AND ITS SUBSIDIARIES
EX-99.1 to Form 6-K
Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress
EX-99.1 to Form 6-K
CytoMed Therapeutics Completes Acquisition of T
EX-99.1 to Form 6-K
INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
EX-99.1 to Form 6-K
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL
EX-99.2 to Form 6-K
on recent acquisition - CytoMed Therapeutics expands into auto-immune
EX-99.1 to Form 6-K
Therapeutics Limited Announces At-the-Market (ATM) Offering Program
EX-99.1 to Form 6-K
CytoMed Therapeutics Reports Full Year Ended December
EX-99.1 to Form 6-K
on Clinical Milestone - CytoMed Therapeutics
EX-99.1 to Form 6-K
Therapeutics’ first-in-human Phase I ANGELICA clinical trial using
EX-99.1 to Form 6-K
AGREEMENT IS MADE THIS 6 TH DAY F MAY 2024
EX-99.2 to Form 6-K
INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
EX-99.1 to Form 6-K
INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
EX-99.1 to Form 6-K
Patent Granted for CytoMed Therapeutics’ Licensed iPSC-based Technology
EX-99.1 to Form 6-K
Therapeutics Limited Announces Pricing of Initial Public Offering
EX-99.1 to Form 6-K